my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
10-11-2011: Evotec AG announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology.
As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules against a selected number of targets. The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.
Evotec will receive research funding based on the resource allocated over the projects and will be further rewarded on achieving the goals of the research collaboration with early stage discovery, preclinical and clinical milestones. In addition Evotec will receive royalties based on net sales of any approved drugs from the collaboration.
Dr Werner Lanthaler, Chief Executive Officer at Evotec stated: "We are extremely pleased that UCB has again selected Evotec to collaborate on this second significant Drug Discovery Collaboration. This integrated drug discovery deal showcases our broad target class expertise coupled with our industry leading platform. We look forward to a fruitful collaboration with our scientific colleagues and friends at UCB."
Dr Ismail Kola, President, UCB NewMedicines commented: "Evotec is the ideal partner to provide the resource bandwidth and drug-hunting expertise to complement our internal efforts to progress this strategically important program."
No financial details are disclosed.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
4-Antibody AG and Evotec AG Form Strategic Collaboration
4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high ... more
Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi
Evotec AG announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments. Evotec and Shionogi will continue to collaborate to progress the fragments through the drug discovery process ... more
Evotec and APEIRON Biologics start next project on the Cbl-b target
Evotec AG and Apeiron Biologics AG announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enh ... more
Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more
Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more
Cimzia shows positive top-line phase 3 results in axial spondyloarthritis and ankylosing spondylitis
UCB announced positive top-line results from the phase 3 study designed to evaluate the efficacy and safety of certolizumab pegol in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases which includes ankylosing spondylitis (AS)."The ... more
UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president ... more
UCB and Oxford University announce new R&D partnership
UCB Pharma and Oxford University agreed to collaborate on cutting-edge pharmaceutical research projects, enabling scientists from industry and academia to work together to develop medicines to treat serious diseases in immunology and neurology. These combined resources and expertise will gi ... more
With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in three therapeutic areas - CNS, inflammation and oncology. more
UCB, Brussels, Belgium is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflam ... more
UCB, Brussels, Belgium is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflam ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
